Benzatropine (INN),[2] known as benztropine in the United States and Japan,[3] is a medication used to treat movement disorders like parkinsonism and dystonia, as well as extrapyramidal side effects of antipsychotics, including akathisia.

[5][6] Common side effects include dry mouth, blurry vision, nausea, and constipation.

[10] Benzatropine is also sometimes used for the treatment of dystonia, a rare disorder that causes abnormal muscle contraction, resulting in twisting postures of limbs, trunk, or face.

In terms of its anticholinergic activity, it is specifically an antimuscarinic and acts a selective muscarinic acetylcholine M1 and M3 receptor antagonist.

[17] Benzatropine has been also identified, by a high throughput screening approach, as a potent differentiating agent for oligodendrocytes, possibly working through M1 and M3 muscarinic receptors.

Benzatropine and analogues are atypical dopamine reuptake inhibitors,[19] which might make them useful for people with akathisia secondary to antipsychotic therapy.

[3] "Benztropine" is the official United States Adopted Name (USAN), the medication naming system coordinated by the USAN Council, co-sponsored by the American Medical Association (AMA), the United States Pharmacopeial Convention (USP), and the American Pharmacists Association (APhA).